Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of...

por Shimura, Masahiko, Kitano, Shigehiko, Ogata, Nahoko, Mitamura, Yoshinori, Oh, Hideyasu, Ochi, Haruka, Ohsawa, Shino, Hirakata, Akito
Publicado 2023

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phas...

por Mori, Ryusaburo, Honda, Shigeru, Gomi, Fumi, Tsujikawa, Akitaka, Koizumi, Hideki, Ochi, Haruka, Ohsawa, Shino, Okada, Annabelle Ayame
Publicado 2023

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE...

por Takahashi, Kanji, Cheung, Chui Ming Gemmy, Iida, Tomohiro, Lai, Timothy Y. Y., Ohji, Masahito, Yanagi, Yasuo, Kawano, Mika, Ohsawa, Shino, Suzuki, Tomoyuki, Kotecha, Aachal, Lin, Hugh, Patel, Vaibhavi, Swaminathan, Balakumar, Lee, Won Ki
Publicado 2023